Patient Safety Organizations: Voluntary Relinquishment for the Institute for Safe Medication Practices (ISMP), 53003-53004 [2020-18877]
Download as PDF
Federal Register / Vol. 85, No. 167 / Thursday, August 27, 2020 / Notices
A. Purpose
GENERAL SERVICES
ADMINISTRATION
[OMB Control No. 3090–0250; Docket No.
2020–0001; Sequence No. 7]
Information Collection; General
Services Administration Acquisition
Regulation; Zero Burden Information
Collection Reports
Office of the Chief Acquisition
Officer, General Services
Administration (GSA).
ACTION: Notice of request for public
comments regarding an extension to an
existing OMB information collection.
AGENCY:
Under the provisions of the
Paperwork Reduction Act, the
Regulatory Secretariat Division (MVCB)
will be submitting to the Office of
Management and Budget (OMB) a
request to review and approve an
extension of a previously approved
information collection requirement
regarding Zero Burden Information
Collection Reports.
DATES: Submit comments on or before:
October 26, 2020.
ADDRESSES: Submit comments
identified by Information Collection
3090–0250, Zero Burden Information
Collection Reports via https://
www.regulations.gov. Submit comments
via the Federal eRulemaking portal by
searching the OMB control number
3090–0250. Select the link ‘‘Comment
Now’’ that corresponds with
‘‘Information Collection 3090–0250,
Zero Burden Information Collection
Reports’’. Follow the instructions
provided on the screen. Please include
your name, company name (if any), and
‘‘Information Collection 3090–0250,
Zero Burden Information Collection
Reports’’ on your attached document.
Instructions: Please submit comments
only and cite Information Collection
3090–0250, Zero Burden Information
Collection Reports, in all
correspondence related to this
collection. Comments received generally
will be posted without change to
regulations.gov, including any personal
and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check regulations.gov, approximately
two-to-three days after submission to
verify posting.
FOR FURTHER INFORMATION CONTACT: Mr.
Thomas O’Linn, Procurement Analyst,
General Services Acquisition Policy, at
202–445–0390 or via email at
Thomas.olinn@gsa.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:09 Aug 26, 2020
Jkt 250001
This information requirement consists
of reports that do not impose collection
burdens upon the public. These
collections require information which is
already available to the public at large,
or that is routinely exchanged by firms
during the normal course of business. A
general control number for these
collections decreases the amount of
paperwork generated by the approval
process.
Under clause 552.238–73,
‘‘Identification of Electronic Office
Equipment Providing Accessibility for
the Handicapped,’’ (previous clause
number 552.238–70) the offeror is
encouraged to identify office equipment,
including any special peripheral that
will facilitate electronic office
equipment accessibility for
handicapped individuals in its
commercial catalogs and pricelists
accepted by the Government.
B. Annual Reporting Burden
None.
C. Public Comments
Public comments are particularly
invited on: Whether this collection of
information is necessary and whether it
will have practical utility; whether our
estimate of the public burden of this
collection of information is accurate and
based on valid assumptions and
methodology; and ways to enhance the
quality, utility, and clarity of the
information to be collected.
Obtaining Copies of Proposals:
Requesters may obtain a copy of the
information collection documents from
the General Services Administration,
Regulatory Secretariat Division (MVCB),
1800 F Street NW, Washington, DC
20405, telephone 202–501–4755.
Please cite OMB Control No. 3090–
0250, Zero Burden Information
Collection Reports, in all
correspondence.
Jeffrey A. Koses,
Senior Procurement Executive, Office of
Acquisition Policy, Office of Governmentwide Policy.
[FR Doc. 2020–18799 Filed 8–26–20; 8:45 am]
BILLING CODE 6820–61–P
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
53003
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
Patient Safety Organizations:
Voluntary Relinquishment for the
Institute for Safe Medication Practices
(ISMP)
Agency for Healthcare Research
and Quality (AHRQ), Department of
Health and Human Services (HHS).
ACTION: Notice of delisting.
AGENCY:
The Patient Safety and
Quality Improvement Final Rule
(Patient Safety Rule) authorizes AHRQ,
on behalf of the Secretary of HHS, to list
as a patient safety organization (PSO) an
entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ by
the Secretary if it is found to no longer
meet the requirements of the Patient
Safety and Quality Improvement Act of
2005 (Patient Safety Act) and Patient
Safety Rule, when a PSO chooses to
voluntarily relinquish its status as a
PSO for any reason, or when a PSO’s
listing expires. AHRQ accepted a
notification of proposed voluntary
relinquishment from the Institute for
Safe Medication Practices (ISMP), PSO
number P0009, of its status as a PSO,
and has delisted the PSO accordingly.
DATES: The delisting was effective at
12:00 Midnight ET (2400) on August 17,
2020.
ADDRESSES: The directories for both
listed and delisted PSOs are ongoing
and reviewed weekly by AHRQ. Both
directories can be accessed
electronically at the following HHS
website: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT:
Cathryn Bach, Center for Quality
Improvement and Patient Safety, AHRQ,
5600 Fishers Lane, MS 06N100B,
Rockville, MD 20857; Telephone (toll
free): (866) 403–3697; Telephone (local):
(301) 427–1111; TTY (toll free): (866)
438–7231; TTY (local): (301) 427–1130;
Email: pso@ahrq.hhs.gov.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Background
The Patient Safety Act, 42 U.S.C.
299b–21 to 299b–26, and the related
Patient Safety Rule, 42 CFR part 3,
published in the Federal Register on
November 21, 2008 (73 FR 70732–
70814), establish a framework by which
individuals and entities that meet the
definition of provider in the Patient
Safety Rule may voluntarily report
information to PSOs listed by AHRQ, on
a privileged and confidential basis, for
E:\FR\FM\27AUN1.SGM
27AUN1
53004
Federal Register / Vol. 85, No. 167 / Thursday, August 27, 2020 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
the aggregation and analysis of patient
safety events.
The Patient Safety Act authorizes the
listing of PSOs, which are entities or
component organizations whose
mission and primary activity are to
conduct activities to improve patient
safety and the quality of health care
delivery. HHS issued the Patient Safety
Rule to implement the Patient Safety
Act. AHRQ administers the provisions
of the Patient Safety Act and Patient
Safety Rule relating to the listing and
operation of PSOs. The Patient Safety
Rule authorizes AHRQ to list as a PSO
an entity that attests that it meets the
statutory and regulatory requirements
for listing. A PSO can be ‘‘delisted’’ if
it is found to no longer meet the
requirements of the Patient Safety Act
and Patient Safety Rule, when a PSO
chooses to voluntarily relinquish its
status as a PSO for any reason, or when
a PSO’s listing expires. Section 3.108(d)
of the Patient Safety Rule requires
AHRQ to provide public notice when it
removes an organization from the list of
PSOs.
AHRQ has accepted a notification of
proposed voluntary relinquishment
from the Institute for Safe Medication
Practices (ISMP) to voluntarily
relinquish its status as a PSO.
Accordingly, the Institute for Safe
Medication Practices (ISMP), P0009,
was delisted effective at 12:00 Midnight
ET (2400) on August 17, 2020. Institute
for Safe Medication Practices (ISMP) has
patient safety work product (PSWP) in
its possession. The PSO will meet the
requirements of section 3.108(c)(2)(i) of
the Patient Safety Rule regarding
notification to providers that have
reported to the PSO and of section
3.108(c)(2)(ii) regarding disposition of
PSWP consistent with section
3.108(b)(3). According to section
3.108(b)(3) of the Patient Safety Rule,
the PSO has 90 days from the effective
date of delisting and revocation to
complete the disposition of PSWP that
is currently in the PSO’s possession.
More information on PSOs can be
obtained through AHRQ’s PSO website
at https://www.pso.ahrq.gov.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0088]
Privacy Act of 1974; System of
Records
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of a new system of
records.
AGENCY:
Virginia L. Mackay-Smith,
Associate Director.
In accordance with the
requirements of the Privacy Act of 1974,
as amended, the Department of Health
and Human Services (HHS) is
establishing a new system of records to
be maintained by the Centers for Disease
Control and Prevention, 09–20–0180,
‘‘Electronic Import Permit Program
Portal (eIPP Portal).’’ The system of
records will be used by CDC to monitor
the importation of infectious biological
agents, infectious substances, and
vectors of human disease.
DATES: The modified system of records
is applicable August 27, 2020, subject to
a 30-day period in which to comment
on the routine uses. Written comments
must be received on or before
September 28, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2020–
0088 by any of the following methods:
• Federal eRulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Beverly Walker, Chief Privacy
Officer, CDC Privacy Unit,
CyberSecurity Program Office (CSPO),
Centers for Disease Control and
Prevention, 4770 Buford Hwy., Mailstop
S101, Atlanta, GA 30341.
Instructions: All submissions received
must include the agency name and
Docket Number. All relevant comments
received will be posted without change
to https://regulations.gov, including any
personal information provided.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. For access to the docket to
read background documents or
comments received, go to https://
www.regulations.gov.
[FR Doc. 2020–18877 Filed 8–26–20; 8:45 am]
FOR FURTHER INFORMATION CONTACT:
BILLING CODE 4160–90–P
Beverly Walker, Chief Privacy Officer,
CDC Privacy Unit, CyberSecurity
Program Office (CSPO), Centers for
Disease Control and Prevention, 4770
Buford Hwy., Mailstop S101, Atlanta,
GA 30341. Telephone: 770–488–8524.
VerDate Sep<11>2014
17:09 Aug 26, 2020
Jkt 250001
SUMMARY:
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
SUPPLEMENTARY INFORMATION:
I. Background on the CDC Import
Permit Program
Under the authority of Section 361 of
the Public Health Service Act (PHS Act)
(42 U.S.C. 264), the HHS Secretary
makes and enforces such regulations as
in his/her judgment are necessary to
prevent the introduction, transmission,
or spread of communicable diseases
from foreign countries into the U.S.
states or territories. For purposes of
carrying out and enforcing such
regulations, the HHS Secretary may
authorize a variety of public health
measures, including inspection,
fumigation, disinfection, sanitation, pest
extermination, destruction of animals or
articles found to be sources of
dangerous infection to human beings,
and other measures. The Foreign
Quarantine regulations (42 CFR part 71)
set forth provisions to prevent the
introduction, transmission, and spread
of communicable disease from foreign
countries into the United States. Part 71,
Subpart F (Importations) contains
provisions governing the importation of
infectious biological agents, infectious
substances, and vectors (42 CFR 71.54),
including requiring persons to obtain a
permit issued by the CDC before
importing, or distributing after import,
any of these materials. The purpose of
the import permit requirement and
permitting process is to prevent the
introduction, transmission, or spread of
communicable diseases from foreign
countries into the U.S. states or
territories. Before issuing an import
permit, the CDC Division of Select
Agents and Toxins, Import Permit
Program (CDC/IPP) reviews the
application to ensure the applicant has
appropriate safety measures in place for
importing and working safely with the
applicable infectious biological agent(s),
substance(s), and/or vector(s).
Regulations of the U.S. Department of
Transportation apply to such materials
while in transit in the U.S. states and
territories.
II. New System of Records 09–20–0180
The proposed new system of records,
‘‘Electronic Import Permit Program
Portal (eIPP Portal),’’ will cover records
about individual applicants, which the
CDC/IPP maintains in the new eIPP
Portal information technology (IT)
system for the purpose of overseeing—
and issuing permits allowing—the
importation of infectious biological
agents, infectious substances, and
vectors of human disease as outlined in
the import permit regulations at 42 CFR
71.54. The eIPP Portal IT system is a
single web-based information
E:\FR\FM\27AUN1.SGM
27AUN1
Agencies
[Federal Register Volume 85, Number 167 (Thursday, August 27, 2020)]
[Notices]
[Pages 53003-53004]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-18877]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Patient Safety Organizations: Voluntary Relinquishment for the
Institute for Safe Medication Practices (ISMP)
AGENCY: Agency for Healthcare Research and Quality (AHRQ), Department
of Health and Human Services (HHS).
ACTION: Notice of delisting.
-----------------------------------------------------------------------
SUMMARY: The Patient Safety and Quality Improvement Final Rule (Patient
Safety Rule) authorizes AHRQ, on behalf of the Secretary of HHS, to
list as a patient safety organization (PSO) an entity that attests that
it meets the statutory and regulatory requirements for listing. A PSO
can be ``delisted'' by the Secretary if it is found to no longer meet
the requirements of the Patient Safety and Quality Improvement Act of
2005 (Patient Safety Act) and Patient Safety Rule, when a PSO chooses
to voluntarily relinquish its status as a PSO for any reason, or when a
PSO's listing expires. AHRQ accepted a notification of proposed
voluntary relinquishment from the Institute for Safe Medication
Practices (ISMP), PSO number P0009, of its status as a PSO, and has
delisted the PSO accordingly.
DATES: The delisting was effective at 12:00 Midnight ET (2400) on
August 17, 2020.
ADDRESSES: The directories for both listed and delisted PSOs are
ongoing and reviewed weekly by AHRQ. Both directories can be accessed
electronically at the following HHS website: https://www.pso.ahrq.gov/listed.
FOR FURTHER INFORMATION CONTACT: Cathryn Bach, Center for Quality
Improvement and Patient Safety, AHRQ, 5600 Fishers Lane, MS 06N100B,
Rockville, MD 20857; Telephone (toll free): (866) 403-3697; Telephone
(local): (301) 427-1111; TTY (toll free): (866) 438-7231; TTY (local):
(301) 427-1130; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Background
The Patient Safety Act, 42 U.S.C. 299b-21 to 299b-26, and the
related Patient Safety Rule, 42 CFR part 3, published in the Federal
Register on November 21, 2008 (73 FR 70732-70814), establish a
framework by which individuals and entities that meet the definition of
provider in the Patient Safety Rule may voluntarily report information
to PSOs listed by AHRQ, on a privileged and confidential basis, for
[[Page 53004]]
the aggregation and analysis of patient safety events.
The Patient Safety Act authorizes the listing of PSOs, which are
entities or component organizations whose mission and primary activity
are to conduct activities to improve patient safety and the quality of
health care delivery. HHS issued the Patient Safety Rule to implement
the Patient Safety Act. AHRQ administers the provisions of the Patient
Safety Act and Patient Safety Rule relating to the listing and
operation of PSOs. The Patient Safety Rule authorizes AHRQ to list as a
PSO an entity that attests that it meets the statutory and regulatory
requirements for listing. A PSO can be ``delisted'' if it is found to
no longer meet the requirements of the Patient Safety Act and Patient
Safety Rule, when a PSO chooses to voluntarily relinquish its status as
a PSO for any reason, or when a PSO's listing expires. Section 3.108(d)
of the Patient Safety Rule requires AHRQ to provide public notice when
it removes an organization from the list of PSOs.
AHRQ has accepted a notification of proposed voluntary
relinquishment from the Institute for Safe Medication Practices (ISMP)
to voluntarily relinquish its status as a PSO. Accordingly, the
Institute for Safe Medication Practices (ISMP), P0009, was delisted
effective at 12:00 Midnight ET (2400) on August 17, 2020. Institute for
Safe Medication Practices (ISMP) has patient safety work product (PSWP)
in its possession. The PSO will meet the requirements of section
3.108(c)(2)(i) of the Patient Safety Rule regarding notification to
providers that have reported to the PSO and of section 3.108(c)(2)(ii)
regarding disposition of PSWP consistent with section 3.108(b)(3).
According to section 3.108(b)(3) of the Patient Safety Rule, the PSO
has 90 days from the effective date of delisting and revocation to
complete the disposition of PSWP that is currently in the PSO's
possession.
More information on PSOs can be obtained through AHRQ's PSO website
at https://www.pso.ahrq.gov.
Virginia L. Mackay-Smith,
Associate Director.
[FR Doc. 2020-18877 Filed 8-26-20; 8:45 am]
BILLING CODE 4160-90-P